Investigating Whether Acute Elevation of Fatty Acid Levels Alters Cerebral Glucose Transport and Metabolism

Last updated: March 28, 2025
Sponsor: University of North Carolina, Chapel Hill
Overall Status: Active - Recruiting

Phase

1/2

Condition

Diabetes Prevention

Obesity

Treatment

Intralipid, 20% Intravenous Emulsion

Placebos

Clinical Study ID

NCT04328337
22-2455
1R01DK123227-01
  • Ages 18-45
  • All Genders
  • Accepts Healthy Volunteers

Study Summary

The goal of this study is to understand the role of brain glucose transport in individuals with obesity and the association with cerebral hypometabolism and these individuals' response to plasma glucose elevations. The main premise is that obesity leads to reduced brain glucose transport and that we can measure this reduction with magnetic resonance spectroscopy (MRS). The secondary premises are that this reduction is driven by elevated non esterified fatty acids which act to turn on specific signaling pathways that regulate brain GLUT1 levels.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Age 18-45 years

  • HbA1C <6.5%

  • Normal weight individuals: BMI 17-25 kg/m^2

  • Obese individuals: BMI >30 kg/m^2

Exclusion

Exclusion Criteria:

  • Creatinine >1.5mg/dL

  • Hematocrit <35% for females and <39% for males

  • ALT and AST >2.5X upper limit of normal

  • Abnormal TSH

  • Abnormal PT/PTT/INR

  • Triglycerides >200 mg/dL

  • Known hepatic, gastrointestinal, renal, neurologic, psychiatric, cerebrovasculardisease

  • Uncontrolled hypertension

  • Current or past 3 months use of ketogenic diet

  • Use of any medications, vitamins, or supplements that can alter cerebral metabolismor lipids

  • Smoking

  • Current or recent steroid use in last 6 months

  • >5% body weight change in last 6 months

  • Illicit drug use/alcoholism

  • Inability to enter MRI/MRS

  • For women: pregnancy, seeking pregnancy, or breastfeeding

Study Design

Total Participants: 40
Treatment Group(s): 2
Primary Treatment: Intralipid, 20% Intravenous Emulsion
Phase: 1/2
Study Start date:
December 08, 2020
Estimated Completion Date:
June 01, 2026

Study Description

There are 2 aims of this study. The intent of aim 1 is to measure the effect of obesity on glucose transport and metabolism in the human brain. This study aim will be conducted in non-diabetic, obese individuals and age- and HbA1c-matched normal weight individuals. A total of 15 non-diabetic - normal weight individuals and 15 obese individuals will be enrolled.

The second aim randomizes 40 non-diabetic, normal weight individuals. The intent of aim 2 is to determine whether acute elevation of NEFA levels in lean, healthy individuals will alter cerebral glucose transport. Eligible participants will be randomized (1:1) to receive either intralipid or normal saline.

The focus of this protocol registration is the randomized portion of the study (aim 2).

Connect with a study center

  • Yale School of Medicine

    New Haven, Connecticut 06519
    United States

    Site Not Available

  • Biomedical Research Imaging Center Marsico Hall (UNC)

    Chapel Hill, North Carolina 27514
    United States

    Active - Recruiting

  • Clinical and Translational Research Center (CTRC) Burnett-Womack Building (UNC)

    Chapel Hill, North Carolina 27514
    United States

    Active - Recruiting

  • University of North Carolina at Chapel Hill

    Chapel Hill, North Carolina 27514
    United States

    Active - Recruiting

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.